Tag Archives: Life Science

99 New Pharmaceutical Biotechnology and Healthcare Projects Drive Major Facility Investments in April 2026

JACKSONVILLE, Fla., May 27, 2026 (SEND2PRESS NEWSWIRE) — Industrial manufacturing activity remained strong in April 2026, led by sustained investment from the pharmaceutical, medical device, biotechnology, and healthcare sectors. Industrial SalesLeads research team identified 60 pharmaceutical, medical device, and biotechnology projects, along with 39 healthcare-related projects, signaling continued demand for facility modernization, expansion, and operational upgrades across the U.S. and Canada.

Image caption: Industrial SalesLeads, Inc.

The following are selected highlights on new Life Science industry news:

LIFE SCIENCES – BY PROJECT TYPE

Pharmaceutical, Medical Device, Biotechnology – 60

Healthcare – 39

LIFE SCIENCES – BY PROJECT LOCATION (TOP 5 STATES)

California – 12

Massachusetts – 11

Virginia – 10

Texas – 8

Michigan – 6

LIFE SCIENCES – BY PROJECT SCOPE/ACTIVITY

Renovation/Equipment Upgrade – 76

Relocation – 60

Expansion/Equipment Upgrade – 14

New Construction – 8

LIFE SCIENCES EQUIPMENT CATEGORIES IN DEMAND

In the month of April, identified life sciences project managers are procuring the following equipment:

80–89%: Lighting (85.9%), Networking/Security Equipment (82.8%)

40–49%: Building Renovation (47.5%)

10–19%: Compressed Air Systems, HVAC Equipment, Mechanical Construction, Fire Protection Equipment, Material Handling/Storage Equipment, Building Construction, Loading Dock Equipment, Conveyors, Heat Exchangers, Control Systems & Instrumentation

9%: Floor Coatings

7%: Air Emissions Control Equipment, Packaging Equipment, Tanks/Vessels – Stainless, Equipment Relocation

TOP 10 TRACKED LIFE SCIENCES PROJECTS

FLORIDA:

Healthcare provider is planning to invest $55 million for new construction of a 14,500sf medical and office in FL. They are currently seeking approval for the project.

GEORGIA:

Healthcare service provider has recently started a 317,000 sf expansion and renovation of their hospital in Cumming, GA. Completion is slated for late 2028.

OHIO:

Biotechnology company is planning to invest $18 million for the expansion and renovation of their warehouse, office, and laboratory facility in OH. They are currently seeking approval for the project. Construction is expected to start in Summer 2026.

MASSACHUSETTS:

Medical device manufacturer is planning for an expansion of their manufacturing facility in MA. They are currently seeking approval for the project.

MINNESOTA:

Pharmaceutical company is planning for the expansion and equipment upgrades on their processing facility in MN. They are currently seeking approval for the project.

MISSOURI:

Pharmaceutical company is planning for the construction of a processing facility in MO. They are currently seeking approval for the project.

NORTH CAROLINA:

Specialty healthcare service provider is planning to invest $2.7 million for the renovation of 10,000 sf of medical and office space in NC. They are currently seeking approval for the project.

NEW JERSEY:

Healthcare service provider is planning to invest $600 million for a 444,000 sf expansion of their hospital in NJ. They are currently seeking approval for the project.

NORTHERN CALIFORNIA:

Healthcare service provider is planning to invest $8 million for the renovation of a recently leased 39,000 sf of medical and office space at CA. They have recently received approval for the project.

NEW YORK:

Healthcare service provider is investing $21 million for the expansion and renovation of their medical and office facilities in NY. Completion is slated for late 2026.

LARGEST PLANNED PROJECT

The largest project is owned by Shine Technologies. Medical isotope technology company is constructing a processing facility in Janesville, WI. Completion is slated for Summer 2027.

ABOUT INDUSTRIAL SALESLEADS, INC.

Since 1959, Industrial SalesLeads, based in Jacksonville, FL is a leader in delivering industrial capital project intelligence and prospecting services for sales and marketing teams to ensure a predictable and scalable pipeline. Our Industrial Market Intelligence, IMI identifies timely insights on companies planning significant capital investments such as new construction, expansion, relocation, equipment modernization and plant closings in industrial facilities. The Outsourced Prospecting Services, an extension to your sales team, is designed to drive growth with qualified meetings and appointments for your internal sales team. Visit us at https://salesleadsinc.com/.

Each month, our team provides hundreds of industrial reports within a variety of industries.

Learn more at:

https://www.salesleadsinc.com/data-solutions/industrial-project-reports/

https://www.salesleadsinc.com/blog/

NEWS SOURCE: Industrial SalesLeads Inc

This press release was issued on behalf of the news source (Industrial SalesLeads Inc), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/99-new-pharmaceutical-biotechnology-and-healthcare-projects-drive-major-facility-investments-in-april-2026/

BioAustinCTX Announces Leadership Transition

AUSTIN, Texas, March 18, 2026 (SEND2PRESS NEWSWIRE) — BioAustinCTX today announced that Scott Collins, PhD, has transitioned from his role as President at the end of February after more than a decade of leadership supporting the growth of the Central Texas life sciences ecosystem.

Image caption: BioAustinCTX.

During his tenure over the past decade, Dr. Collins helped guide BioAustinCTX through a period of significant expansion for the region’s biotechnology and life science community. Under his leadership, the organization strengthened its role as a connector across startups, established companies, academic institutions, investors, and economic development partners, helping foster collaboration and visibility across the ecosystem.

“Serving as President of BioAustinCTX has been one of the great privileges of my professional career,” said Dr. Collins. “I am proud of the progress our community has made and look forward to continuing to support the organization as Ambassador and Past President while focusing on advancing deep technology and biotechnology innovation in the Central Texas region.”

Following this transition, Dr. Collins will remain actively engaged with BioAustinCTX in an Ambassador and Past President capacity, supporting the organization’s mission and ongoing initiatives.

As BioAustinCTX looks ahead, the organization remains focused on strengthening the connectivity, competitiveness, and growth of the Central Texas life sciences sector. The Board of Directors is committed to building on the strong foundation established to date and will share additional updates regarding leadership and strategic priorities in the coming weeks.

BioAustinCTX thanks Dr. Collins for his service and leadership and looks forward to continued collaboration as the organization enters its next phase.

About BioAustinCTX

BioAustinCTX is a nonprofit industry organization dedicated to advancing the life sciences ecosystem in Central Texas. Through collaboration, education, networking, and strategic engagement, BioAustinCTX supports entrepreneurs, researchers, companies, and partners working to bring life-changing technologies to market. Learn more at https://bioaustinctx.com/.

NEWS SOURCE: BioAustinCTX

This press release was issued on behalf of the news source (BioAustinCTX), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/bioaustinctx-announces-leadership-transition/

HLA Protein Technologies Announces Next-Gen HLA Product Lines and Strategic Investment

OKLAHOMA CITY, Okla., Sept. 30, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) reports that its new manufacturing expansion is positioned to support the Company’s growth. A new product line launch, a strategic investment led by a private investor group; and a corporate rebrand to HLA Protein Technologies, reflects the company’s expanded focus on advanced immunology and oncology research tools.

Image caption: HLA Protein Technologies, Inc.

The new investment will fund accelerated product development and expanded manufacturing capacity at the company’s Oklahoma City headquarters, with additional hiring across R&D, bioprocess and commercial operations. HLA Protein Technologies will scale production capacity, implement expanded QC/QA frameworks and enhance GMP‑adjacent processes suitable for research‑use‑only (RUO) products.

The company expects to add roles across protein biochemistry, cell biology, manufacturing operations and commercial support. Facility enhancements will prioritize throughput, reproducibility and documentation standards to align with customer expectations in biopharma R&D.

And, the rebrand to HLA Protein Technologies unifies the company’s legacy of protein engineering with its expanded mission: delivering best‑in‑class HLA research tools and services to customers across biopharma, diagnostics and translational research. This transition establishes a brand identity that mirrors the company’s core scientific strengths and customer value proposition in HLA‑based research tools. The new name and visual identity will roll out across product labels, documentation and digital properties over the coming weeks.

“This is a pivotal moment in our company’s evolution,” said Dr. Rico Buchli, Chief Scientist at HLA Protein Technologies. “Our new HLA portfolio pairs rigorously characterized reagents with custom services that help biopharma teams accelerate target discovery and validation, immune monitoring and mechanism‑of‑action studies. The rebrand reflects our commitment to leadership in HLA‑enabled solutions.”

Anchored by two decades of expertise in soluble HLA engineering and peptide–MHC technologies, the new product lines will feature next‑generation Class I and Class II HLA tetramers, new product formats and custom peptide‑loaded complexes designed for high‑throughput discovery, screening and translational studies.

This portfolio will be complemented by custom assay development and engineered cell line services to support biopharma and academic partners advancing immunotherapies and vaccine research. These new products will complement the Company’s existing portfolio of more than 275 HLA Class I and Class II alleles; it will be made available to the scientific community at https://hlaprotein.com/.

“Oklahoma’s life sciences ecosystem is gaining momentum, and HLA Protein Technologies’ growth exemplifies that trajectory,” said Michelle Gregory, Director, Life Science Oklahoma. “The company’s expansion and investment in local manufacturing aligns with our mission to advance U.S.-based innovation and bioproduction.”

About HLA Protein Technologies, Inc.

HLA Protein Technologies, Inc., based in Oklahoma City, Oklahoma, specializes in high‑purity HLA proteins, engineered cell lines and custom assay development. With a focus on immunology and oncology, the company provides HLA‑based reagents and services that enable discovery, lead validation and translational research. HLA Protein Technologies serves leading pharma, diagnostic and research customers in more than 20 countries.

Public and media queries: https://www.hlaprotein.com/contact-us

MULTIMEDIA:

Logo link for media: https://www.Send2Press.com/300dpi/25-0930-s2p-hlaprot-300dpi.webp

NEWS SOURCE: HLA Protein Technologies Inc.

This press release was issued on behalf of the news source (HLA Protein Technologies Inc.), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/hla-protein-technologies-announces-next-gen-hla-product-lines-and-strategic-investment/

Fluid Metering, Inc. Unveils FENYX: A Revolutionary Leap in Fluidic Precision

SYOSSET, N.Y. /ScoopCloud/ -- Fluid Metering Inc., a leading manufacturer of fluid control solutions, proudly announces the debut of its groundbreaking variable dispense pump, FENYX (patent pending), heralding a new era of fluidic precision. Crafted to meet the evolving needs of the life sciences field, the FENYX integrates an advanced miniaturized fluidic system, enabling precise control of microliter volumes across a wide spectrum of applications.

Not only does the FENYX variable dispense pump streamline flushing, priming, and dispensing into a single, cohesive unit, it also offers unmatched flexibility, allowing dispensing over various surfaces or wells through non-contact dispensing without requiring physical intervention. Pioneering components, such as a calibratable flag, anti-backlash mechanism, and encoder, address the escalating demand for heightened throughput, single microliter dispense volumes, and minimized downtime.

Harnessing Fluid Metering's renowned CeramPump(R) technology, the FENYX boasts a sleek, low-profile design, delivering the industry's expected levels of precision and accuracy even while dispensing over air. This breakthrough innovation is poised to redefine fluidic solutions within the diagnostic, biotechnology & medical device space, playing a pivotal role in achieving impactful outcomes.

"The FENYX isn't just a pump; it's a symbol of Fluid Metering's commitment to innovation and our relentless pursuit of excellence in fluidic solutions. The FENYX marks our bold entry into the variable dispense pump market, expanding our capabilities beyond fixed dispense pumps. Join us as we embark on this exciting journey towards shaping the future of fluidic precision in life sciences," said Sean Madden, Vice President, Commercial and Product Development at Fluid Metering Inc.

Learn more: https://www.fluidmetering.com/fenyx

About Fluid Metering Inc.:

Fluid Metering Inc. stands at the forefront of fluid control innovation, having revolutionized the industry with our patented valve-less rotating and reciprocating piston metering pump concept, providing unmatched pumping excellence and precise fluid control across Diagnostics, Biotechnology, and Medical Device applications. With over 60 years of OEM design experience, our engineering team is dedicated to meeting customer and application requirements with unparalleled accuracy, precision, and reliability.

Learn more at: https://www.fluidmetering.com/

Fluid Metering Inc., a leading manufacturer of fluid control solutions, proudly announces the debut of its groundbreaking variable dispense pump, FENYX (patent pending), heralding a new era of fluidic precision. Crafted to meet the evolving needs of the life sciences field, the FENYX integrates an advanced miniaturized fluidic system, enabling precise control of microliter volumes across a wide spectrum of applications.

Related link: https://www.fluidmetering.com/

Fluid Metering Announces New Distribution Partnership with Girtec AG

SYOSSET, N.Y. /ScoopCloud/ -- Fluid Metering Inc. (FMI) is pleased to announce that Switzerland-based Girtec AG was recently appointed a strategic distributor to cover sales of our ultra-precise fluid control metering and dispensing products in Germany, Switzerland, Austria, and Liechtenstein.

Girtec AG, founded in 2012, provides its fluidic products and services in the fields of medical, laboratory and analytical technology instrumentation while developing innovative reliable solutions in close cooperation with its customers.

"This recent distribution partnership is more than just a collaboration - it is the beginning of a groundbreaking era for first-class products and innovation in our market. This partnership not only brings outstanding products into the hands of our customers, but also sets a new benchmark for quality, reliability, and technological excellence. We proudly combine first-class products with our local presence to offer our customers unique added value," as stated by Christoph Girsberger, CEO and Owner at Girtec AG.

"We are excited about this strategic alliance between both organizations to help meet the growing demand for ultra precise microfluidic pumps for medical and life sciences applications within the region," as stated by Sean Madden, Vice President of Commercial and Product Development at Fluid Metering.

About Fluid Metering Inc.:

Fluid Metering, Inc. pioneered the first patented valveless rotating and reciprocating piston metering pump concept delivering pumping excellence and precise fluid control for OEM, Medical and Life Science applications. Fluid Metering's engineering team incorporates over 60 years of OEM design experience to meet specific customer and application requirements with Accuracy, Precision & Reliability!

Fluid Metering Inc. was established in 1959 and is headquartered in Syosset, New York.

Website: https://www.fluidmetering.com/

Fluid Metering Inc. (FMI) is pleased to announce that Switzerland-based Girtec AG was recently appointed a strategic distributor to cover sales of our ultra-precise fluid control metering and dispensing products in Germany, Switzerland, Austria, and Liechtenstein.

Related link: https://www.fluidmetering.com/

Divergent CRO Announces Launch of New Contract Research Organization

ATLANTA, Ga. /ScoopCloud/ -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

With an unwavering commitment to excellence, Divergent CRO provides a wide range of services, including clinical trial management, regulatory affairs, data management, biostatistics, and medical writing. By leveraging our extensive expertise, we are dedicated to helping our clients accelerate the development of innovative biopharmaceuticals and medical devices.

Our team of highly skilled professionals, including experienced clinical researchers, project managers, and regulatory specialists, is dedicated to delivering the highest standards of quality and efficiency throughout each stage of the clinical trial process. We understand the challenges faced by biotech and device companies and are committed to providing flexible and cost-effective solutions to meet their specific needs.

Divergent CRO is equipped with cutting-edge technology and infrastructure to ensure the smooth execution of clinical trials. Our advanced data management systems and secure facilities ensure the confidentiality and integrity of study data, while our robust quality assurance processes guarantee compliance with regulatory requirements.

"We are thrilled to launch our new Contract Research Organization and partner with biotech and device companies to advance the development of life-changing therapies," said Divergent CRO's Owner-Partners. "Our team is dedicated to delivering exceptional results and providing the highest level of service to our clients. With our expertise and commitment to excellence, we are confident that we can make a significant impact on the success of their clinical programs."

Divergent CRO is now accepting inquiries and is available to discuss collaboration opportunities with biotech and device companies seeking to enhance their clinical research capabilities.

For more information, please visit Divergentcro.com or contact our business development team at Customerservice@divergentcro.com or (888) 342-1447.

About Divergent CRO:

Divergent CRO is a leading provider of clinical services to biotech and device companies. With a focus on innovation and quality, we strive to accelerate the development of life-changing therapies through our comprehensive and tailored clinical services. We thrive on leaving our clients and patients satisfied by improving human health and wellness. Our team of experts is dedicated to delivering exceptional results and providing the highest level of service to our clients. At Divergent CRO, we don't just manage clinical trials; we craft personalized solutions, striving to be the difference by transforming challenges into triumphs in the pursuit of groundbreaking healthcare innovation.

Learn more at: https://divergentcro.com/

Social Links:

LinkedIn Page: https://www.linkedin.com/company/divergentcro/

Instagram: https://www.instagram.com/divergent.cro/

TikTok: https://www.tiktok.com/@divergentcro1

YouTube: https://www.youtube.com/@DivergentCRO

Featured Podcasts:

The Jali Podcast - Melyssa Barrett/DivergentCRO - https://melyssabarrett.com/the-jali-podcast/

Episode Thirty-one - AMY HUTTO, PRODUCTIVITY COACH - https://amyhutto.com/podcast/s1ep30

Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

Related link: https://divergentcro.com/

BioAustinCTX Adds Hilary Graham, PhD, to the Board of Directors

AUSTIN, Texas /ScoopCloud/ -- BioAustinCTX, Central Texas' Life Science industry organization, announced today the appointment of Hilary Graham, PhD to its Board of Directors. Hilary has studied and worked in the Central Texas life science ecosystem since 2005. She is a storyteller and commercial strategist with a growth mindset specializing in the molecular diagnostics and life sciences markets. Connecting people is her passion.

"Expanding the board with diverse members that represent the biotech community in Central Texas is our present focus with the planned appointment of three to five additional board members by year-end," said Scott Collins, Board of Directors President. "We're excited to have Hilary join us as she brings marketing expertise rooted in customer centricity and a wealth of connections from her 18 years in the Austin and Life Science Reagents/Diagnostic communities."

Hilary leads Marketing for the Molecular Diagnostics Division of Bio-Techne, which includes the Asuragen, Exosome Diagnostics, Armored Molecular Controls, and Companion Diagnostics franchises. In this divisional leadership role, she's responsible for portfolio strategy, product management, and content marketing. Previously to Bio-Techne, Hilary led marketing and application science for the xMAP multiplexing franchise at Luminex and was leading the launch of the INTELLIFLEX system upon departure. Before joining Luminex, Hilary worked in a variety of commercial and technical communications roles at Syneos Health and UT MD Anderson Cancer Center.

"I remember going to BioAustin events early in my graduate training at UT Austin and I'm delighted to come full circle from an event attendee to a member of the BioAustinCTX board," said Hilary Graham. "I look forward to driving enhanced strategic value for the community at large as well as establishing a forum for commercial professionals living in Austin to connect via the establishment of special interest groups focused on marketing and sales as pilots with additional professional disciplines to follow."

About BioAustinCTX:

BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region. Visit BioAustinCTX for more information https://bioaustinctx.com, email: operations@bioaustinctx.com

BioAustinCTX, Central Texas' Life Science industry organization, announced today the appointment of Hilary Graham, PhD to its Board of Directors. Hilary has studied and worked in the Central Texas life science ecosystem since 2005. She is a storyteller and commercial strategist with a growth mindset specializing in the molecular diagnostics and life sciences markets. Connecting people is her passion.

Related link: https://bioaustinctx.com/

Fluid Metering Announces New Distributor in UK and Ireland

SYOSSET, N.Y. /ScoopCloud/ -- Fluid Metering Inc., a pioneer in design and manufacturing of high-performance fluid handling solutions, is pleased to announce a new distribution agreement with Premier Control Technologies Limited (PCT) as the new distributor of precision fluid control solutions throughout the United Kingdom and Ireland.

Fluid Metering Inc, and PCT are well aligned with their company ethos, at the forefront is collaboration with both its suppliers and customers to ensure all expectations are met working within the science and laboratory segments, as well as the broader life sciences sector. Foremost, this alliance allows us to be well placed to be your partner of choice for your next project or OEM requirement.

"PCT are proud to be the partner of choice for Fluid Metering Inc, the technical and commercial needs of UK and Irish customers can now be met with local service and support," says James Kybird, Managing Director at Premier Control Technologies Limited. "Based in Hethel, Norfolk, our sales office remains the first point of contact with business development managers placed throughout the UK offering market and product expertise for customer applications requiring engineering support."

"Fluid Metering, Inc. is excited to have found a partner within the UK and Ireland that shares FMI's commitment to customer service and will be able to further our customer's success in those markets with local support," says Sean Madden, Vice President of Commercial & Product Development at Fluid Metering, Inc.

About Fluid Metering Inc.:

Fluid Metering continues to be a leader in the manufacturing of valve-less ceramic dispensers and metering pumps with strategic focus in the life science market space. Proudly, incorporating over 64 years of OEM design and experience to meet customer specific application requirements with Accuracy, Precision & Reliability!

Learn more at: https://www.fluidmetering.com/

Fluid Metering, Inc., a pioneer in design and manufacturing of high-performance fluid handling solutions, is pleased to announce a new distribution agreement with Premier Control Technologies Limited (PCT) as the new distributor of precision fluid control solutions throughout the United Kingdom and Ireland.

Related link: https://www.fluidmetering.com/

Dosaggio by SottoPelle Partners with Cerbo

SCOTTSDALE, Ariz. /ScoopCloud/ -- Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

Dosaggio™, the original, multi-patented hormone therapy dosing platform for physicians, announces its exciting new partnership with Cerbo electronic health records (EMR). This collaboration offers medical providers a powerful and seamless integration of capabilities for bioidentical hormone replacement therapy practices.

This partnership brings together Cerbo's robust functional EHR with the advanced and powerful Dosaggio™ hormone dosing tool, enabling medical providers to expand their functional medicine practices into the bioidentical hormone therapy arena.

Cerbo is a functional, full-service EHR that offers customized and integrated scheduling, charting, billing, reporting, prescription management, and treatment plan solutions for medical practices. The Cerbo EHR offers flexibility for each provider's needs - all with fair pricing.

The Dosaggio™ bioidentical hormone pellet therapy dosing application allows medical providers to optimize their patient's hormone health through precise, individualized hormone dosing. Dosaggio™ by SottoPelle® offers providers a proprietary online hormone dosing calculator that uses the patient's unique health data to calculate a precise, individualized BHRT dose. Dosaggio™ combines a powerful algorithm with on-screen clinical guidance that enables medical providers to approach each patient's hormone health care in an individualized manner.

The integration of these two platforms allows medical providers to pull patient data such as lab work, demographics, past hormone therapy notes, and other documentation from their Cerbo EHR into the Dosaggio™ dosing application. This eliminates the need for double documentation and helps seamlessly maintain continuity of care for BHRT patients.

"The Dosaggio and Cerbo integration will help providers bring quality care to their patients who suffer from hormonal imbalance," stated CarolAnn Tutera, CEO of Dosaggio™ by SottoPelle®. "It is our mission to help providers bring individualized care to more patients, to help them age gracefully."

Practices that are currently using Cerbo's EHR can conveniently set up their Dosaggio™ account by visiting the integrations page within their account.

Medical providers who are interested in learning more about this exciting integration may visit: https://sottopelle.health.

Learn more about SottoPelle® Therapy at: https://www.sottopelletherapy.com/.

Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

Related link: https://www.sottopelletherapy.com/

BioAustinCTX Announces Board of Director Leadership Changes

AUSTIN, Texas /ScoopCloud/ -- Life Science industry organization, BioAustinCTX, announced today changes to its Board of Directors with the departure of Elisa Maldonado-Holmertz and the appointment of Tami Annable. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S.

With more than 240 companies and a variety of community ecosystem organizations involved in building the life science sector, Central Texas emerged as a life science innovation wellspring attracting investment for early-stage startups and relocations for established companies. BioAustinCTX serves as the premier membership organization facilitating the growth of the life science industry in Central Texas by fostering communication, collaboration and engagement across all key stakeholders.

Elisa Maldonado-Holmertz, served on the Board of Directors for BioAustinCTX since 2017. Elisa's leadership and countless hours of support helped to guide the strategic direction and tactical execution of the organization throughout her entire tenure. Elisa played a principal role in producing the monthly BioAustinCTX/TMDA newsletter and coordinating BioAustinCTX's BioBash, the most successful life science industry networking event in Central Texas for more than a decade.

Scott Collins, President of BioAustinCTX stated, "Elisa's dedication and contributions to the evolution of BioAustinCTX are greatly appreciated and we wish her great success on her future endeavors."

Tami Annable joins the BioAustinCTX Board of Directors effective 01 April 2022. Tami is a well-known member of the life science industry in Central Texas having previously served as the Executive Director of the Temple Health and Bioscience Economic Development District Incubator for the past six years. Tami brings a wealth of professional experience in the healthcare and pharmaceutical industry as well as operational experience working with life science startup companies.

BioAustinCTX is undertaking an expanding range of initiatives and programs supporting continued growth of the life science industry with the goal of establishing the region as a global life sciences economic hub. This evolving strategy will encompass new programs to build collaboration, communication, and growth across companies, community partners, and academic institutions focused on the life science sector.

About BioAustinCTX:

BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region. Visit BioAustinCTX for more information https://bioaustinctx.com, email: operations@bioaustinctx.com

Life Science industry organization, BioAustinCTX, announced today changes to its Board of Directors with the departure of Elisa Maldonado-Holmertz and the appointment of Tami Annable. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S.

Related link: https://bioaustinctx.com/